MA26607A1 - Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant - Google Patents
Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenantInfo
- Publication number
- MA26607A1 MA26607A1 MA25457A MA25457A MA26607A1 MA 26607 A1 MA26607 A1 MA 26607A1 MA 25457 A MA25457 A MA 25457A MA 25457 A MA25457 A MA 25457A MA 26607 A1 MA26607 A1 MA 26607A1
- Authority
- MA
- Morocco
- Prior art keywords
- piperidine
- treatment
- diseases including
- neuronal degeneration
- drugs containing
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98102246 | 1998-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26607A1 true MA26607A1 (fr) | 2004-12-20 |
Family
ID=8231382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA25457A MA26607A1 (fr) | 1998-02-10 | 1999-02-05 | Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6015824A (fr) |
| EP (1) | EP0937458B1 (fr) |
| JP (1) | JP3142527B2 (fr) |
| KR (1) | KR100319249B1 (fr) |
| CN (1) | CN1144789C (fr) |
| AR (1) | AR018077A1 (fr) |
| AT (1) | ATE285766T1 (fr) |
| AU (1) | AU748335B2 (fr) |
| BR (1) | BR9900742A (fr) |
| CA (1) | CA2260698A1 (fr) |
| CZ (1) | CZ41099A3 (fr) |
| DE (1) | DE69922858T2 (fr) |
| DK (1) | DK0937458T3 (fr) |
| ES (1) | ES2245808T3 (fr) |
| HR (1) | HRP990042A2 (fr) |
| HU (1) | HUP9900275A3 (fr) |
| ID (1) | ID23456A (fr) |
| IL (2) | IL128389A0 (fr) |
| MA (1) | MA26607A1 (fr) |
| NO (1) | NO990609L (fr) |
| NZ (1) | NZ334081A (fr) |
| PE (1) | PE20000276A1 (fr) |
| PL (1) | PL331336A1 (fr) |
| PT (1) | PT937458E (fr) |
| SG (1) | SG74120A1 (fr) |
| TR (1) | TR199900286A2 (fr) |
| YU (1) | YU5899A (fr) |
| ZA (1) | ZA991038B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2793245B1 (fr) * | 1999-05-05 | 2002-10-11 | Adir | Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6369078B1 (en) * | 1999-08-31 | 2002-04-09 | J. Phillip Bowen | Solenopsin derivatives and analogues as fire ant suppressants |
| JP4219590B2 (ja) * | 2000-04-20 | 2009-02-04 | エフ.ホフマン−ラ ロシュ アーゲー | ピロリジン及びピペリジン誘導体並びに神経変性障害の治療のためのこれらの使用 |
| WO2002050070A2 (fr) | 2000-12-21 | 2002-06-27 | Warner-Lambert Company Llc | Derives de piperidine en tant qu'antagonistes vis-a-vis de n-methyl-d-aspartate (nmda), avec selectivite en termes de sous-type |
| MXPA02002749A (es) | 2001-03-27 | 2002-10-28 | Warner Lambert Co | Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato. |
| US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| NZ588698A (en) * | 2008-03-27 | 2012-06-29 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| EP2470021B1 (fr) * | 2009-08-27 | 2014-10-22 | Merck Sharp & Dohme Corp. | Nouveaux agonistes de récepteurs adrénergiques bêta 3 dérivés de pyrrolidine |
| BR112012004333A2 (pt) * | 2009-08-27 | 2015-09-08 | Merck Sharp & Dohme | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3941796A (en) * | 1970-05-21 | 1976-03-02 | Minnesota Mining And Manufacturing Company | α-(Hydroxy and alkoxy substituted)phenyl-α-(2-piperidinyl)-methanols |
| US4407670A (en) * | 1980-02-28 | 1983-10-04 | National Research Development Corporation | Biocidal compounds and compositions |
| US4342692A (en) * | 1980-10-20 | 1982-08-03 | Usv Pharmaceutical Corporation | Pyrrolidines |
| ZA825227B (en) * | 1981-07-22 | 1984-03-28 | Syntex Inc | Substituted pyrrolidine cardiovascular system regulators antihypertensives |
| IL70752A0 (en) * | 1983-01-24 | 1984-06-29 | Syntex Inc | (+-)2-(3,4-methylenedioxyphenethyl)-5-(3-carbamoyl-alpha,4-dihydroxybenzyl)pyrrolidines and salts thereof,their preparation and pharmaceutical compositions containing them |
| FI840255A7 (fi) * | 1983-01-24 | 1984-07-25 | Syntex Inc | Menetelmä valmistaa antihypertensiivisia 2-/fenetyyli/-5-/(3,4-metyleenidioksi)- - hydroksibentsyyli/pyrrolidiineja. |
| US4569941A (en) * | 1983-03-21 | 1986-02-11 | Usv Pharmaceutical Corp. | Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal |
| US4548951A (en) * | 1983-04-21 | 1985-10-22 | Syntex (U.S.A.) Inc. | Hypotensive benzoxathiole pyrrolidines |
| US4558066A (en) * | 1984-05-17 | 1985-12-10 | Syntex (U.S.A.) Inc. | Treatment and prevention of ocular hypertension |
| US4632929A (en) * | 1985-01-17 | 1986-12-30 | Usv Pharmaceutical Corp. | Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives |
-
1999
- 1999-01-20 US US09/234,266 patent/US6015824A/en not_active Expired - Fee Related
- 1999-02-02 ES ES99102078T patent/ES2245808T3/es not_active Expired - Lifetime
- 1999-02-02 DK DK99102078T patent/DK0937458T3/da active
- 1999-02-02 DE DE69922858T patent/DE69922858T2/de not_active Expired - Fee Related
- 1999-02-02 EP EP99102078A patent/EP0937458B1/fr not_active Expired - Lifetime
- 1999-02-02 AT AT99102078T patent/ATE285766T1/de not_active IP Right Cessation
- 1999-02-02 PT PT99102078T patent/PT937458E/pt unknown
- 1999-02-05 IL IL12838999A patent/IL128389A0/xx unknown
- 1999-02-05 CZ CZ99410A patent/CZ41099A3/cs unknown
- 1999-02-05 NZ NZ334081A patent/NZ334081A/xx unknown
- 1999-02-05 BR BR9900742-8A patent/BR9900742A/pt not_active IP Right Cessation
- 1999-02-05 MA MA25457A patent/MA26607A1/fr unknown
- 1999-02-05 CA CA002260698A patent/CA2260698A1/fr not_active Abandoned
- 1999-02-06 KR KR1019990004058A patent/KR100319249B1/ko not_active Expired - Fee Related
- 1999-02-08 HU HU9900275A patent/HUP9900275A3/hu unknown
- 1999-02-08 SG SG1999000363A patent/SG74120A1/en unknown
- 1999-02-08 AU AU16354/99A patent/AU748335B2/en not_active Ceased
- 1999-02-08 JP JP11029850A patent/JP3142527B2/ja not_active Expired - Fee Related
- 1999-02-08 PE PE1999000101A patent/PE20000276A1/es not_active Application Discontinuation
- 1999-02-08 AR ARP990100528A patent/AR018077A1/es unknown
- 1999-02-09 ID IDP990095A patent/ID23456A/id unknown
- 1999-02-09 ZA ZA9901038A patent/ZA991038B/xx unknown
- 1999-02-09 HR HR98102246.0A patent/HRP990042A2/hr not_active Application Discontinuation
- 1999-02-09 NO NO990609A patent/NO990609L/no not_active Application Discontinuation
- 1999-02-09 PL PL99331336A patent/PL331336A1/xx unknown
- 1999-02-09 YU YU5899A patent/YU5899A/sh unknown
- 1999-02-10 TR TR1999/00286A patent/TR199900286A2/xx unknown
- 1999-02-10 CN CNB991018001A patent/CN1144789C/zh not_active Expired - Fee Related
- 1999-07-28 US US09/362,932 patent/US6153624A/en not_active Expired - Fee Related
-
2001
- 2001-07-19 IL IL14445601A patent/IL144456A0/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69322710D1 (de) | Vorrichtung zum Sammeln und Mischen von biologischen/pharmazeutischen Medien | |
| FI990268L (fi) | Ei-peptidi-NK-antagonistin käytt¦ ihosairauksien ja kutinan hoitoon tarkoitettujen lääkkeiden valmistukseen | |
| NO994014D0 (no) | Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer | |
| CY2007001I2 (el) | Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη | |
| FI963696L (fi) | Geeli ihosairauksien hoitoon ja ihon desinfiointiin | |
| DE69631531D1 (de) | Katheter zur verabreidung von arzneien | |
| EP1117357A4 (fr) | Procedes et dispositifs servant a ameliorer l'administration de composes actifs sur le plan pharmaceutique | |
| MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
| DE69513672D1 (de) | Verbesserte vorrichtung zur iontophoretischen verabreichung von medikamenten | |
| ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
| MA26607A1 (fr) | Utilisation de derives de piperidine et de pyrrolidine pour le traitement de maladies comprenant des formes de degenerescence neuronale et medicaments les contenant | |
| DE69825625D1 (de) | Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen | |
| DE19580261D2 (de) | Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion | |
| ATE318604T1 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
| DE3875866D1 (de) | Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie. | |
| NO307930B1 (no) | Benzo[f]kinolinoner, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av formulering for behandling | |
| DE69939075D1 (de) | Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten | |
| DE69838785D1 (de) | Pharmazeutische mittel zur behandlung von zerebralen amyloidosis | |
| DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
| PT932400E (pt) | Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica | |
| FR2717080B1 (fr) | Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales. | |
| FI971527L (fi) | Indolijohdannaisten käyttö erilaisten sairauksien hoitoon | |
| MA26683A1 (fr) | Derives de piperidine, procede pour leur preparation, medicaments les contenant et leur utilisation dans le traitement de troubles neurologiques et physiologiques | |
| MA26650A1 (fr) | Oxo-thia -azabicyclooctenes, preparations pharmaceutiques les contenant, et leur utilisation pour le traitement et la prophylaxie de maladies infectieuses. | |
| TR199901385T2 (xx) | Piperidin t�revleri. |